Brief: Hookipa Announces Positive Phase 2 Results For Cmv Vaccine Candidate Hb‑101

So-Young International

22/06/2020 12:17

June 22 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA ANNOUNCES POSITIVE PHASE 2 INTERIM SAFETY AND
IMMUNOGENICITY RESULTS FOR ITS CMV VACCINE CANDIDATE HB-101
    * HOOKIPA PHARMA INC - INTERIM DATA DEMONSTRATE THAT HB-101
IS
WELL TOLERATED
    * HOOKIPA PHARMA INC - HB-101 ELICITS T CELL AND B CELL
RESPONSES
IN TARGET POPULATION
    * HOOKIPA PHARMA INC - PLAN TO REPORT PRELIMINARY EFFICACY
DATA
AND UPDATED SAFETY AND IMMUNOGENICITY DATA BY END OF 2020
    * HOOKIPA PHARMA - PATIENTS WHO RECEIVED 3 DOSES OF HB-101
SHOW
COMPARABLE IMMUNOGENICITY TO HEALTHY VOLUNTEERS IN PHASE 1
CLINICAL TRIAL OF HB-101

Source text for Eikon:  ID:nGNX3V7CVy 
Further company coverage:  HOOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))